Loading...
Loading...
JSPR| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.3M |
| Gross Profit | -0.3M |
| Operating Expense | 14.8M |
| Operating I/L | -15.1M |
| Other Income/Expense | 1.3M |
| Interest Income | 1.4M |
| Pretax | -13.7M |
| Income Tax Expense | 0.2M |
| Net Income/Loss | -13.7M |
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development and commercialization of conditioning agents and stem cell engineering for hematopoietic stem cell transplantation and gene therapies. Its lead product candidate, JSP191, is a conditioning antibody designed to clear hematopoietic stem cells from bone marrow in patients prior to allogeneic stem cell therapy or stem cell gene therapy. The company also focuses on developing engineered hematopoietic stem cells to address limitations of gene-edited stem cell grafts, aiming to expand the use of stem cell transplantation and ex vivo gene therapy.
